Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist
Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon/GI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer ce
| Condition(s) | Cancer, Breast Cancer, Prostate Cancer, Colon Cancer, GI Cancers, Ovarian Cancer, Pancreatic Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon/GI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a st |
| Who can participate | Inclusion Criteria: * Receiving germline testing related to primary cancer condition initiated by oncologist * 18 years old or older. * Speak and read English Exclusion Criteria: * Receiving cancer genetic testing via a referral to a genetics clinic * Do not speak or read English * Under 18 years of age * Determined to have diminished, marginal and or fluctuating decisional capacity * Lack access to internet or an electronic device |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Unity Health Toronto |
| Locations | Toronto, Ontario, Canada; Toronto, Ontario, Canada |
| Start date | 2026-05 |
| NCT ID | NCT07387263 |
| Official listing | https://clinicaltrials.gov/study/NCT07387263 |